ArticleInternational journal of cancer2025

TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study.

Eliana Bignotti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.